Page last updated: 2024-11-01

nimodipine and Basal Ganglia Diseases

nimodipine has been researched along with Basal Ganglia Diseases in 1 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research Excerpts

ExcerptRelevanceReference
"2."1.30Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice. ( Amorim, SC; Costa, PG; Futuro-Neto, HA; Pires, JG; Ribeiro, CA; Saraiva, FP, 1999)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Futuro-Neto, HA1
Costa, PG1
Amorim, SC1
Saraiva, FP1
Ribeiro, CA1
Pires, JG1

Other Studies

1 other study available for nimodipine and Basal Ganglia Diseases

ArticleYear
Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice.
    Progress in neuro-psychopharmacology & biological psychiatry, 1999, Volume: 23, Issue:2

    Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Calcium Channel Blockers; Catalepsy; Dose-Res

1999